Home › Companies › BioMarin Pharmaceutical Inc. › 2025-2026
Compiled from SEC Form N-PX filings and BioMarin Pharmaceutical Inc.’s Form 8-K (Item 5.07 on EDGAR). Page generated 02 October 2026.
Explore BioMarin Pharmaceutical Inc. in the interactive database Compare manager voting policies
These tallies are BioMarin Pharmaceutical Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.
| Ballot item | For | Against | Abstain | Withheld | Broker non-votes | Outcome |
|---|---|---|---|---|---|---|
| Elect Director: Elizabeth M. Anderson | 152,826,855 | 11,325,400 | 41,995 | -- | 11,619,042 | Majority: yes |
| Elect Director: Barbara W. Bodem | 162,832,241 | 796,989 | 565,020 | -- | 11,619,042 | Majority: yes |
| Elect Director: Ian T. Clark | 144,380,101 | 19,160,530 | 653,619 | -- | 11,619,042 | Majority: yes |
| Elect Director: Athena Countouriotis | 162,326,065 | 1,823,399 | 44,786 | -- | 11,619,042 | Majority: yes |
| Elect Director: Willard Dere | 161,112,606 | 2,973,541 | 108,103 | -- | 11,619,042 | Majority: yes |
| Elect Director: Mark J. Enyedy | 161,113,325 | 3,032,040 | 48,885 | -- | 11,619,042 | Majority: yes |
| Elect Director: Alexander Hardy | 163,115,633 | 1,028,506 | 50,111 | -- | 11,619,042 | Majority: yes |
| Elect Director: Maykin Ho | 160,849,437 | 3,300,117 | 44,696 | -- | 11,619,042 | Majority: yes |
| Elect Director: Robert J. Hombach | 160,262,501 | 3,342,524 | 589,225 | -- | 11,619,042 | Majority: yes |
| Elect Director: Timothy P. Walbert | 158,544,683 | 5,554,116 | 95,451 | -- | 11,619,042 | Majority: yes |
| Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The ratification of the selection of KPMG LLP as BioMarin's independent registered public accounting firm for the fiscal year ending December 31, 2026, as set forth in t | 170,867,335 | 4,850,526 | 95,431 | -- | -- | Majority: yes |
| Proposal 3: Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote to approve the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement, received the following votes: | 142,742,800 | 21,287,767 | 163,683 | -- | 11,619,042 | Majority: yes |
| Proposal 4: Approval of an Amendment to the 2017 Equity Incentive Plan The approval of the Plan Amendment received the following votes: | 158,561,867 | 5,480,380 | 152,003 | -- | 11,619,042 | Majority: yes |
Source: BioMarin Pharmaceutical Inc., Form 8-K — read the filing on EDGAR.
Each item below shows how the 511 asset managers that disclosed a BioMarin Pharmaceutical Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of BioMarin Pharmaceutical Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.
Meeting held 2026-06-02.
Combines 12 wordings of this item as funds reported it.
87% Majority: yes · of votes cast
BioMarin Pharmaceutical Inc.’s own tally for this item (“Proposal 3: Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote to approve the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement, received ”): 142,742,800 for, 21,287,767 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 193,268,870 outstanding shares: 74% for, 11% against (85% of the company cast a for/against vote).
The 503 asset managers below cast 89% of the shares they voted on this item FOR. Fund share totals are not shown for this item: fund-reported shares overlap across filings (an adviser and the funds it manages can each report the same shares), and here their sum exceeds the total votes cast at the meeting.
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 28,932,301 | 749,025 | 0 | 0 | For |
| Dodge & Cox | 25,255,784 | 0 | 0 | 0 | For |
| BlackRock | 18,641,257 | 17,633 | 0 | 0 | For |
| PRIMECAP MANAGEMENT CO/CA/ | 13,864,195 | 0 | 0 | 0 | For |
| Fidelity | 9,995,164 | 193,086 | 0 | 0 | For |
| VIKING GLOBAL INVESTORS LP | 6,945,799 | 0 | 0 | 0 | For |
| State Street | 6,862,109 | 52,659 | 0 | 0 | For |
| AQR | 4,347,103 | 0 | 0 | 0 | For |
| GEODE CAPITAL MANAGEMENT, LLC | 3,788,854 | 0 | 0 | 0 | For |
| Capital Research Global Investors | 3,496,878 | 0 | 0 | 0 | For |
| Capital Group | 3,361,286 | 0 | 0 | 0 | For |
| Charles Schwab | 3,236,192 | 899 | 0 | 0 | For |
| Vestal Point Capital, LP | 2,620,148 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,332,341 | 0 | 0 | 0 | For |
| Invesco | 2,318,180 | 0 | 0 | 0 | For |
| Dimensional | 0 | 2,110,825 | 0 | 0 | Against |
| First Trust | 1,604,400 | 1,151 | 0 | 0 | For |
| Citadel | 1,604,159 | 0 | 0 | 0 | For |
| Northern Trust | 1,495,311 | 17,542 | 0 | 0 | For |
| Thrivent | 1,409,227 | 0 | 0 | 0 | For |
| DnB Asset Management AS | 1,236,011 | 0 | 0 | 0 | For |
| Janus Henderson | 1,198,102 | 0 | 0 | 0 | For |
| PICTET ASSET MANAGEMENT SA | 1,180,617 | 0 | 0 | 0 | For |
| MELLON INVESTMENTS Corp | 1,180,133 | 0 | 0 | 0 | For |
| CAISSE DE DEPOT ET PLACEMENT DU QUEBEC | 0 | 864,198 | 0 | 0 | Against |
Showing the 25 largest of 503 asset managers. See all 503 in the interactive database.
Meeting held 2026-06-02.
Combines 8 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
BioMarin Pharmaceutical Inc.’s own tally for this item (“Proposal 4: Approval of an Amendment to the 2017 Equity Incentive Plan The approval of the Plan Amendment received the following votes:”): 158,561,867 for, 5,480,380 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 193,268,870 outstanding shares: 82% for, 3% against (85% of the company cast a for/against vote).
The 131 asset managers below cast 99.7% of the shares they voted on this item FOR (79,982,574 for, 184,700 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 28,162,774 | 11 | 0 | 0 | For |
| BlackRock | 11,688,363 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,483,325 | 0 | 0 | 0 | For |
| Fidelity | 6,387,963 | 0 | 0 | 0 | For |
| Capital Group | 3,361,286 | 0 | 0 | 0 | For |
| State Street | 2,949,084 | 85 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,332,341 | 0 | 0 | 0 | For |
| First Trust | 1,592,770 | 0 | 0 | 0 | For |
| Charles Schwab | 1,564,652 | 0 | 0 | 0 | For |
| Dimensional | 1,284,559 | 0 | 0 | 0 | For |
| AQR | 763,398 | 0 | 0 | 0 | For |
| Thrivent | 703,036 | 0 | 0 | 0 | For |
| TIAA | 594,303 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 504,880 | 0 | 0 | 0 | For |
| Jackson National | 447,165 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 361,341 | 0 | 0 | 0 | For |
| SEI | 327,820 | 0 | 0 | 0 | For |
| Equitable | 277,210 | 0 | 0 | 0 | For |
| Russell Investments | 249,772 | 0 | 0 | 0 | For |
| John Hancock | 241,920 | 0 | 0 | 0 | For |
| DWS | 230,791 | 0 | 0 | 0 | For |
| Invesco | 222,587 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 221,269 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 211,013 | 0 | 0 | 0 | For |
| Nationwide | 193,491 | 0 | 0 | 0 | For |
Showing the 25 largest of 131 asset managers. See all 131 in the interactive database.
Meeting held 2026-06-02.
Combines 4 wordings of this item as funds reported it.
99.3% Majority: yes · of votes cast
BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Alexander Hardy”): 163,115,633 for, 1,028,506 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 193,268,870 outstanding shares: 84% for, 0.6% against (85% of the company cast a for/against vote).
The 122 asset managers below cast 99.9% of the shares they voted on this item FOR (80,266,665 for, 4,676 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 28,162,783 | 3 | 0 | 0 | For |
| BlackRock | 11,688,363 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,483,325 | 0 | 0 | 0 | For |
| Fidelity | 6,387,963 | 0 | 0 | 0 | For |
| Capital Group | 3,361,286 | 0 | 0 | 0 | For |
| State Street | 2,949,169 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,332,341 | 0 | 0 | 0 | For |
| First Trust | 1,592,770 | 0 | 0 | 0 | For |
| Charles Schwab | 1,564,652 | 0 | 0 | 0 | For |
| Dimensional | 1,284,559 | 0 | 0 | 0 | For |
| AQR | 763,398 | 0 | 0 | 0 | For |
| Thrivent | 703,036 | 0 | 0 | 0 | For |
| TIAA | 594,303 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 504,880 | 0 | 0 | 0 | For |
| Jackson National | 447,165 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 361,341 | 0 | 0 | 0 | For |
| SEI | 327,820 | 0 | 0 | 0 | For |
| Equitable | 277,210 | 0 | 0 | 0 | For |
| Russell Investments | 249,772 | 0 | 0 | 0 | For |
| John Hancock | 241,920 | 0 | 0 | 0 | For |
| DWS | 230,791 | 0 | 0 | 0 | For |
| Invesco | 222,587 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 221,269 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 211,013 | 0 | 0 | 0 | For |
| Nationwide | 193,491 | 0 | 0 | 0 | For |
Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.
Meeting held 2026-06-02.
Combines 5 wordings of this item as funds reported it.
99% Majority: yes · of votes cast
BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Athena Countouriotis”): 162,326,065 for, 1,823,399 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 193,268,870 outstanding shares: 84% for, 1.0% against (85% of the company cast a for/against vote).
The 122 asset managers below cast 99.9% of the shares they voted on this item FOR (80,266,663 for, 4,678 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 28,162,781 | 5 | 0 | 0 | For |
| BlackRock | 11,688,363 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,483,325 | 0 | 0 | 0 | For |
| Fidelity | 6,387,963 | 0 | 0 | 0 | For |
| Capital Group | 3,361,286 | 0 | 0 | 0 | For |
| State Street | 2,949,169 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,332,341 | 0 | 0 | 0 | For |
| First Trust | 1,592,770 | 0 | 0 | 0 | For |
| Charles Schwab | 1,564,652 | 0 | 0 | 0 | For |
| Dimensional | 1,284,559 | 0 | 0 | 0 | For |
| AQR | 763,398 | 0 | 0 | 0 | For |
| Thrivent | 703,036 | 0 | 0 | 0 | For |
| TIAA | 594,303 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 504,880 | 0 | 0 | 0 | For |
| Jackson National | 447,165 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 361,341 | 0 | 0 | 0 | For |
| SEI | 327,820 | 0 | 0 | 0 | For |
| Equitable | 277,210 | 0 | 0 | 0 | For |
| Russell Investments | 249,772 | 0 | 0 | 0 | For |
| John Hancock | 241,920 | 0 | 0 | 0 | For |
| DWS | 230,791 | 0 | 0 | 0 | For |
| Invesco | 222,587 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 221,269 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 211,013 | 0 | 0 | 0 | For |
| Nationwide | 193,491 | 0 | 0 | 0 | For |
Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.
Meeting held 2026-06-02.
Combines 5 wordings of this item as funds reported it.
99.5% Majority: yes · of votes cast
BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Barbara W. Bodem”): 162,832,241 for, 796,989 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 193,268,870 outstanding shares: 84% for, 0.5% against (85% of the company cast a for/against vote).
The 122 asset managers below cast 99.9% of the shares they voted on this item FOR (80,266,664 for, 4,674 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 28,162,782 | 1 | 0 | 0 | For |
| BlackRock | 11,688,363 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,483,325 | 0 | 0 | 0 | For |
| Fidelity | 6,387,963 | 0 | 0 | 0 | For |
| Capital Group | 3,361,286 | 0 | 0 | 0 | For |
| State Street | 2,949,169 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,332,341 | 0 | 0 | 0 | For |
| First Trust | 1,592,770 | 0 | 0 | 0 | For |
| Charles Schwab | 1,564,652 | 0 | 0 | 0 | For |
| Dimensional | 1,284,559 | 0 | 0 | 0 | For |
| AQR | 763,398 | 0 | 0 | 0 | For |
| Thrivent | 703,036 | 0 | 0 | 0 | For |
| TIAA | 594,303 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 504,880 | 0 | 0 | 0 | For |
| Jackson National | 447,165 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 361,341 | 0 | 0 | 0 | For |
| SEI | 327,820 | 0 | 0 | 0 | For |
| Equitable | 277,210 | 0 | 0 | 0 | For |
| Russell Investments | 249,772 | 0 | 0 | 0 | For |
| John Hancock | 241,920 | 0 | 0 | 0 | For |
| DWS | 230,791 | 0 | 0 | 0 | For |
| Invesco | 222,587 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 221,269 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 211,013 | 0 | 0 | 0 | For |
| Nationwide | 193,491 | 0 | 0 | 0 | For |
Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.
Meeting held 2026-06-02.
Combines 6 wordings of this item as funds reported it.
93% Majority: yes · of votes cast
BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Elizabeth M. Anderson”): 152,826,855 for, 11,325,400 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 193,268,870 outstanding shares: 79% for, 6% against (85% of the company cast a for/against vote).
The 122 asset managers below cast 97% of the shares they voted on this item FOR (77,616,956 for, 2,654,384 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 28,141,815 | 20,971 | 0 | 0 | For |
| BlackRock | 11,688,363 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,483,325 | 0 | 0 | 0 | For |
| Fidelity | 6,387,963 | 0 | 0 | 0 | For |
| Capital Group | 3,361,286 | 0 | 0 | 0 | For |
| State Street | 2,944,789 | 4,380 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,332,341 | 0 | 0 | 0 | For |
| First Trust | 1,592,770 | 0 | 0 | 0 | For |
| Charles Schwab | 1,564,652 | 0 | 0 | 0 | For |
| Dimensional | 0 | 1,284,559 | 0 | 0 | Against |
| AQR | 763,398 | 0 | 0 | 0 | For |
| Thrivent | 703,036 | 0 | 0 | 0 | For |
| TIAA | 0 | 594,303 | 0 | 0 | Against |
| JANUS INVESTMENT FUND | 504,880 | 0 | 0 | 0 | For |
| Jackson National | 415,047 | 32,118 | 0 | 0 | For |
| Columbia Threadneedle | 361,341 | 0 | 0 | 0 | For |
| SEI | 327,820 | 0 | 0 | 0 | For |
| Equitable | 277,210 | 0 | 0 | 0 | For |
| Russell Investments | 249,772 | 0 | 0 | 0 | For |
| John Hancock | 91,582 | 150,338 | 0 | 0 | Against |
| DWS | 230,791 | 0 | 0 | 0 | For |
| Invesco | 222,587 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 221,269 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 211,013 | 0 | 0 | 0 | For |
| Nationwide | 193,491 | 0 | 0 | 0 | For |
Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.
Meeting held 2026-06-02.
Combines 5 wordings of this item as funds reported it.
88% Majority: yes · of votes cast
BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Ian T. Clark”): 144,380,101 for, 19,160,530 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 193,268,870 outstanding shares: 75% for, 10% against (85% of the company cast a for/against vote).
The 122 asset managers below cast 97% of the shares they voted on this item FOR (78,006,912 for, 2,264,427 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 27,413,765 | 749,019 | 1 | 0 | For |
| BlackRock | 11,688,363 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,483,325 | 0 | 0 | 0 | For |
| Fidelity | 6,367,572 | 20,391 | 0 | 0 | For |
| Capital Group | 3,361,286 | 0 | 0 | 0 | For |
| State Street | 2,944,645 | 4,524 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,332,341 | 0 | 0 | 0 | For |
| First Trust | 1,592,770 | 0 | 0 | 0 | For |
| Charles Schwab | 1,564,652 | 0 | 0 | 0 | For |
| Dimensional | 1,284,559 | 0 | 0 | 0 | For |
| AQR | 763,398 | 0 | 0 | 0 | For |
| Thrivent | 703,036 | 0 | 0 | 0 | For |
| TIAA | 594,303 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 504,880 | 0 | 0 | 0 | For |
| Jackson National | 447,165 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 361,341 | 0 | 0 | 0 | For |
| SEI | 327,820 | 0 | 0 | 0 | For |
| Equitable | 69,448 | 207,762 | 0 | 0 | Against |
| Russell Investments | 0 | 249,772 | 0 | 0 | Against |
| John Hancock | 241,920 | 0 | 0 | 0 | For |
| DWS | 0 | 230,791 | 0 | 0 | Against |
| Invesco | 222,587 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 221,269 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 211,013 | 0 | 0 | 0 | For |
| Nationwide | 182,655 | 10,836 | 0 | 0 | For |
Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.
Meeting held 2026-06-02.
Combines 5 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Mark J. Enyedy”): 161,113,325 for, 3,032,040 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 193,268,870 outstanding shares: 83% for, 2% against (85% of the company cast a for/against vote).
The 122 asset managers below cast 99.0% of the shares they voted on this item FOR (79,509,050 for, 762,290 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 28,151,152 | 11,634 | 0 | 0 | For |
| BlackRock | 11,688,363 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,483,325 | 0 | 0 | 0 | For |
| Fidelity | 6,387,963 | 0 | 0 | 0 | For |
| Capital Group | 3,361,286 | 0 | 0 | 0 | For |
| State Street | 2,949,169 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,332,341 | 0 | 0 | 0 | For |
| First Trust | 1,592,770 | 0 | 0 | 0 | For |
| Charles Schwab | 1,564,652 | 0 | 0 | 0 | For |
| Dimensional | 1,284,559 | 0 | 0 | 0 | For |
| AQR | 763,398 | 0 | 0 | 0 | For |
| Thrivent | 703,036 | 0 | 0 | 0 | For |
| TIAA | 0 | 594,303 | 0 | 0 | Against |
| JANUS INVESTMENT FUND | 504,880 | 0 | 0 | 0 | For |
| Jackson National | 447,165 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 361,341 | 0 | 0 | 0 | For |
| SEI | 327,820 | 0 | 0 | 0 | For |
| Equitable | 277,210 | 0 | 0 | 0 | For |
| Russell Investments | 249,772 | 0 | 0 | 0 | For |
| John Hancock | 241,920 | 0 | 0 | 0 | For |
| DWS | 230,791 | 0 | 0 | 0 | For |
| Invesco | 222,587 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 221,269 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 211,013 | 0 | 0 | 0 | For |
| Nationwide | 193,491 | 0 | 0 | 0 | For |
Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.
Meeting held 2026-06-02.
Combines 4 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Maykin Ho”): 160,849,437 for, 3,300,117 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 193,268,870 outstanding shares: 83% for, 2% against (85% of the company cast a for/against vote).
The 122 asset managers below cast 99.5% of the shares they voted on this item FOR (79,877,924 for, 393,416 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 28,141,835 | 20,951 | 0 | 0 | For |
| BlackRock | 11,688,363 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,483,325 | 0 | 0 | 0 | For |
| Fidelity | 6,387,963 | 0 | 0 | 0 | For |
| Capital Group | 3,361,286 | 0 | 0 | 0 | For |
| State Street | 2,944,789 | 4,380 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,332,341 | 0 | 0 | 0 | For |
| First Trust | 1,592,770 | 0 | 0 | 0 | For |
| Charles Schwab | 1,564,652 | 0 | 0 | 0 | For |
| Dimensional | 1,284,559 | 0 | 0 | 0 | For |
| AQR | 763,398 | 0 | 0 | 0 | For |
| Thrivent | 703,036 | 0 | 0 | 0 | For |
| TIAA | 594,303 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 504,880 | 0 | 0 | 0 | For |
| Jackson National | 447,165 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 361,341 | 0 | 0 | 0 | For |
| SEI | 327,820 | 0 | 0 | 0 | For |
| Equitable | 277,210 | 0 | 0 | 0 | For |
| Russell Investments | 249,772 | 0 | 0 | 0 | For |
| John Hancock | 241,920 | 0 | 0 | 0 | For |
| DWS | 230,791 | 0 | 0 | 0 | For |
| Invesco | 222,587 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 221,269 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 211,013 | 0 | 0 | 0 | For |
| Nationwide | 193,491 | 0 | 0 | 0 | For |
Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.
Meeting held 2026-06-02.
Combines 5 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Robert J. Hombach”): 160,262,501 for, 3,342,524 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 193,268,870 outstanding shares: 83% for, 2% against (85% of the company cast a for/against vote).
The 122 asset managers below cast 99.5% of the shares they voted on this item FOR (79,877,924 for, 393,414 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 28,141,835 | 20,949 | 1 | 0 | For |
| BlackRock | 11,688,363 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,483,325 | 0 | 0 | 0 | For |
| Fidelity | 6,387,963 | 0 | 0 | 0 | For |
| Capital Group | 3,361,286 | 0 | 0 | 0 | For |
| State Street | 2,944,789 | 4,380 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,332,341 | 0 | 0 | 0 | For |
| First Trust | 1,592,770 | 0 | 0 | 0 | For |
| Charles Schwab | 1,564,652 | 0 | 0 | 0 | For |
| Dimensional | 1,284,559 | 0 | 0 | 0 | For |
| AQR | 763,398 | 0 | 0 | 0 | For |
| Thrivent | 703,036 | 0 | 0 | 0 | For |
| TIAA | 594,303 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 504,880 | 0 | 0 | 0 | For |
| Jackson National | 447,165 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 361,341 | 0 | 0 | 0 | For |
| SEI | 327,820 | 0 | 0 | 0 | For |
| Equitable | 277,210 | 0 | 0 | 0 | For |
| Russell Investments | 249,772 | 0 | 0 | 0 | For |
| John Hancock | 241,920 | 0 | 0 | 0 | For |
| DWS | 230,791 | 0 | 0 | 0 | For |
| Invesco | 222,587 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 221,269 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 211,013 | 0 | 0 | 0 | For |
| Nationwide | 193,491 | 0 | 0 | 0 | For |
Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.
Meeting held 2026-06-02.
Combines 5 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Timothy P. Walbert”): 158,544,683 for, 5,554,116 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 193,268,870 outstanding shares: 82% for, 3% against (85% of the company cast a for/against vote).
The 122 asset managers below cast 98% of the shares they voted on this item FOR (78,406,401 for, 1,864,938 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 28,162,770 | 14 | 0 | 0 | For |
| BlackRock | 11,688,363 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,483,325 | 0 | 0 | 0 | For |
| Fidelity | 6,387,963 | 0 | 0 | 0 | For |
| Capital Group | 3,361,286 | 0 | 0 | 0 | For |
| State Street | 2,949,169 | 0 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,332,341 | 0 | 0 | 0 | For |
| First Trust | 1,592,770 | 0 | 0 | 0 | For |
| Charles Schwab | 1,564,652 | 0 | 0 | 0 | For |
| Dimensional | 0 | 1,284,559 | 0 | 0 | Against |
| AQR | 763,398 | 0 | 0 | 0 | For |
| Thrivent | 703,036 | 0 | 0 | 0 | For |
| TIAA | 594,303 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 504,880 | 0 | 0 | 0 | For |
| Jackson National | 415,047 | 32,118 | 0 | 0 | For |
| Columbia Threadneedle | 361,341 | 0 | 0 | 0 | For |
| SEI | 327,820 | 0 | 0 | 0 | For |
| Equitable | 277,210 | 0 | 0 | 0 | For |
| Russell Investments | 249,772 | 0 | 0 | 0 | For |
| John Hancock | 91,582 | 150,338 | 0 | 0 | Against |
| DWS | 230,791 | 0 | 0 | 0 | For |
| Invesco | 222,587 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 221,269 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 211,013 | 0 | 0 | 0 | For |
| Nationwide | 193,491 | 0 | 0 | 0 | For |
Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.
Meeting held 2026-06-02.
Combines 4 wordings of this item as funds reported it.
98% Majority: yes · of votes cast
BioMarin Pharmaceutical Inc.’s own tally for this item (“Elect Director: Willard Dere”): 161,112,606 for, 2,973,541 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 193,268,870 outstanding shares: 83% for, 2% against (85% of the company cast a for/against vote).
The 122 asset managers below cast 99.5% of the shares they voted on this item FOR (79,877,925 for, 393,415 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 28,141,836 | 20,950 | 0 | 0 | For |
| BlackRock | 11,688,363 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,483,325 | 0 | 0 | 0 | For |
| Fidelity | 6,387,963 | 0 | 0 | 0 | For |
| Capital Group | 3,361,286 | 0 | 0 | 0 | For |
| State Street | 2,944,789 | 4,380 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,332,341 | 0 | 0 | 0 | For |
| First Trust | 1,592,770 | 0 | 0 | 0 | For |
| Charles Schwab | 1,564,652 | 0 | 0 | 0 | For |
| Dimensional | 1,284,559 | 0 | 0 | 0 | For |
| AQR | 763,398 | 0 | 0 | 0 | For |
| Thrivent | 703,036 | 0 | 0 | 0 | For |
| TIAA | 594,303 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 504,880 | 0 | 0 | 0 | For |
| Jackson National | 447,165 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 361,341 | 0 | 0 | 0 | For |
| SEI | 327,820 | 0 | 0 | 0 | For |
| Equitable | 277,210 | 0 | 0 | 0 | For |
| Russell Investments | 249,772 | 0 | 0 | 0 | For |
| John Hancock | 241,920 | 0 | 0 | 0 | For |
| DWS | 230,791 | 0 | 0 | 0 | For |
| Invesco | 222,587 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 221,269 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 211,013 | 0 | 0 | 0 | For |
| Nationwide | 193,491 | 0 | 0 | 0 | For |
Showing the 25 largest of 122 asset managers. See all 122 in the interactive database.
Meeting held 2026-06-02.
Combines 3 wordings of this item as funds reported it.
97% Majority: yes · of votes cast
BioMarin Pharmaceutical Inc.’s own tally for this item (“Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The ratification of the selection of KPMG LLP as BioMarin's independent registered public accounting firm for the fiscal year end”): 170,867,335 for, 4,850,526 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 193,268,870 outstanding shares: 88% for, 3% against (91% of the company cast a for/against vote).
The 121 asset managers below cast 99.9% of the shares they voted on this item FOR (80,247,926 for, 19,014 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Vanguard | 28,151,147 | 11,639 | 0 | 0 | For |
| BlackRock | 11,688,363 | 0 | 0 | 0 | For |
| Dodge & Cox | 11,483,325 | 0 | 0 | 0 | For |
| Fidelity | 6,387,963 | 0 | 0 | 0 | For |
| Capital Group | 3,361,286 | 0 | 0 | 0 | For |
| State Street | 2,949,025 | 144 | 0 | 0 | For |
| PRIMECAP Odyssey Funds | 2,332,341 | 0 | 0 | 0 | For |
| First Trust | 1,592,770 | 0 | 0 | 0 | For |
| Charles Schwab | 1,564,652 | 0 | 0 | 0 | For |
| Dimensional | 1,284,559 | 0 | 0 | 0 | For |
| AQR | 763,398 | 0 | 0 | 0 | For |
| Thrivent | 703,036 | 0 | 0 | 0 | For |
| TIAA | 594,303 | 0 | 0 | 0 | For |
| JANUS INVESTMENT FUND | 504,880 | 0 | 0 | 0 | For |
| Jackson National | 447,165 | 0 | 0 | 0 | For |
| Columbia Threadneedle | 361,341 | 0 | 0 | 0 | For |
| SEI | 327,820 | 0 | 0 | 0 | For |
| Equitable | 277,210 | 0 | 0 | 0 | For |
| Russell Investments | 249,772 | 0 | 0 | 0 | For |
| John Hancock | 241,920 | 0 | 0 | 0 | For |
| DWS | 230,791 | 0 | 0 | 0 | For |
| Invesco | 222,587 | 0 | 0 | 0 | For |
| Bridge Builder Trust | 221,269 | 0 | 0 | 0 | For |
| AIG/SunAmerica | 211,013 | 0 | 0 | 0 | For |
| Nationwide | 193,491 | 0 | 0 | 0 | For |
Showing the 25 largest of 121 asset managers. See all 121 in the interactive database.
Meeting held 2026-06-02.
97% Majority: yes · of votes cast
BioMarin Pharmaceutical Inc.’s own tally for this item (“Proposal 4: Approval of an Amendment to the 2017 Equity Incentive Plan The approval of the Plan Amendment received the following votes:”): 158,561,867 for, 5,480,380 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 193,268,870 outstanding shares: 82% for, 3% against (85% of the company cast a for/against vote).
The 5 asset managers below cast 95% of the shares they voted on this item FOR (238,426 for, 13,665 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Eversept Partners, LP | 111,568 | 0 | 0 | 0 | For |
| Empower | 89,408 | 0 | 0 | 0 | For |
| Erste Asset Management GmbH | 37,000 | 0 | 0 | 0 | For |
| WASHINGTON CAPITAL MANAGEMENT, INC | 450 | 9,700 | 0 | 0 | Against |
| Lincoln Financial | 0 | 3,965 | 0 | 0 | Against |
Meeting held 2025-05-20 (outside the 2025-2026 season's 1 July to 30 June window; reported in this season's filings).
Combines 2 wordings of this item as funds reported it.
94% Majority: yes · of votes cast
BioMarin Pharmaceutical Inc.’s own tally for this item (“Proposal 3: Advisory Vote on the Compensation of Named Executive Officers The advisory (non-binding) vote to approve the compensation of BioMarin's named executive officers, as set forth in the Proxy Statement, received ”): 155,351,652 for, 10,227,321 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 193,268,870 outstanding shares: 80% for, 5% against (86% of the company cast a for/against vote).
The 3 asset managers below cast 97% of the shares they voted on this item FOR (8,000 for, 208 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| Investment Management Corp of Ontario | 6,000 | 0 | 0 | 0 | For |
| NORRIS PERNE & FRENCH LLP/MI | 2,000 | 0 | 0 | 0 | For |
| OSSIAM | 0 | 208 | 0 | 0 | Against |
Meeting held 2026-06-02.
97% Majority: yes · of votes cast
BioMarin Pharmaceutical Inc.’s own tally for this item (“Proposal 2: Ratification of the Selection of Independent Registered Public Accounting Firm The ratification of the selection of KPMG LLP as BioMarin's independent registered public accounting firm for the fiscal year end”): 170,867,335 for, 4,850,526 against, per its Form 8-K (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 193,268,870 outstanding shares: 88% for, 3% against (91% of the company cast a for/against vote).
The 2 asset managers below cast 100% of the shares they voted on this item FOR (15,926 for, 0 against).
| Asset manager | For | Against | Abstain | Withheld | Vote |
|---|---|---|---|---|---|
| TEALWOOD ASSET MANAGEMENT INC | 11,526 | 0 | 0 | 0 | For |
| AMERICAN BEACON FUNDS | 4,400 | 0 | 0 | 0 | For |
Ranked by the number of BioMarin Pharmaceutical Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 193,268,870 shares outstanding at the time of that meeting.
| # | Asset manager | % of shares outstanding |
|---|---|---|
| 1 | Vanguard | 15.36% |
| 2 | Dodge & Cox | 13.07% |
| 3 | BlackRock | 9.65% |
| 4 | PRIMECAP MANAGEMENT CO/CA/ | 7.17% |
| 5 | Fidelity | 5.27% |
| 6 | VIKING GLOBAL INVESTORS LP | 3.59% |
| 7 | State Street | 3.58% |
| 8 | AQR | 2.25% |
| 9 | GEODE CAPITAL MANAGEMENT, LLC | 1.96% |
| 10 | Capital Research Global Investors | 1.81% |
Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).
| Holder | % outstanding | Disclosure |
|---|---|---|
| The Vanguard Group | 9.83% | DEF14A |
| BlackRock, Inc. | 9.09% | 13G |
| PRIMECAP Management Company | 8.17% | DEF14A |
| Dodge & Cox | 7.24% | DEF14A |
| State Street | 3.77% | 13F |
| Citadel Advisors | 2.43% | 13F |
| Geode Capital | 1.98% | 13F |
| Dimensional Fund Advisors | 1.97% | 13F |
| FMR (Fidelity) | 1.85% | 13F |
| Morgan Stanley | 1.20% | 13F |
Percentages above are of 193,268,870 shares outstanding, as reported by BioMarin Pharmaceutical Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.
Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from BioMarin Pharmaceutical Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.
At BioMarin Pharmaceutical Inc.'s shareholder meeting held 2026-06-02, in the 2025-2026 proxy season, 511 asset managers reported how they voted in their SEC Form N-PX filings, covering 7,412 separate fund positions. Their filings are grouped here into 16 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — To approve, on an advisory basis, the compensation of the Company's Named Executive Officers as… — FOR was 87% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: BioMarin Pharmaceutical Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission (filing date not recorded for this item).
BioMarin Pharmaceutical Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).